Home › Funds › FARALLON CAPITAL MANAGEMENT, L.L.C. › BEAM

FARALLON CAPITAL MANAGEMENT, L.L.C. position in BEAM

BEAM THERAPEUTICS INC · Health Care

FARALLON CAPITAL MANAGEMENT, L.L.C. reported holding 10,236,396 shares of BEAM (BEAM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$351.3M, representing 1.63% of its reported portfolio and ranking #21 among its reported holdings. FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed BEAM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)10.24M sh
Reported value held$351.31M
Portfolio Weight1.63%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FARALLON CAPITAL MANAGEMENT, L.L.C.'s BEAM position evolved

FARALLON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in BEAM in Q3 2023 at 4,481,839 shares (US$107.8M). The position peaked in Q2 2026 at 10,236,396 shares, worth US$351.3M. Across 12 filings, FARALLON CAPITAL MANAGEMENT, L.L.C. increased the stake 7 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 10,236,396 shares valued at US$351.3M — an increase of 101,700 shares quarter over quarter.. Notable position changes include a 75% increase in Q2 2024 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.48M $107.79M New
Q4 2023 4.11M $111.76M Reduce
Q1 2024 4.51M $149.07M Add
Q2 2024 7.91M $185.40M Add
Q3 2024 8.21M $201.10M Add
Q4 2024 8.24M $204.33M Hold
Q1 2025 9.93M $193.90M Add
Q2 2025 10.01M $170.32M Add
Q3 2025 10.06M $244.23M Hold
Q4 2025 10.06M $278.95M Hold
Q1 2026 10.13M $241.51M Add
Q2 2026 10.24M $351.31M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BEAM and 13F data

BEAM (BEAM THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in BEAM — the largest reported positions include Farallon Capital Management (US$351.3M), ARK Invest (US$351.3M), ARCH Venture Management, LLC (US$155.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BEAM

All BEAM fund holders →

FAQ

How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held BEAM?

FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed BEAM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in BEAM?

As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 10.24M shares of BEAM (BEAM THERAPEUTICS INC), valued at $351.31M, representing 1.63% of its reported portfolio and ranking #21.

Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling BEAM?

In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. increased its position in BEAM. The position peaked in Q2 2026 at 10.24M shares.

Which other funds hold BEAM?

Other major institutional holders of BEAM include Farallon Capital Management, ARK Invest, ARCH Venture Management, LLC, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.